CORDIS - Forschungsergebnisse der EU
CORDIS

EASIVIRAL

Ziel

In September 2016 WHO-Europe stated “Europe is at a critical point with HIV. New diagnoses in the European Region recently increased by 76%”. WHO urges “an accelerated people-centered response” based on taking HIV viral-load (VL) testing out of labs and into local clinics where it is most needed at point-of-care (PoC). No such solution exists today.
New disruptive innovations are needed to address this. AltraTech Ltd has developed three proven biotechnologies to capture, purify, and detect the HIV virus from a blood sample, in 40 mins, using proven HIV biomarkers. This enables life-saving clinical intervention, immediate prescription and therapy for the patient, and stops further spread of the virus. The three techniques are innovative. Their combination, in a portable battery-operated kit format, is disruptive. It offers the unique combination of portability, robustness, reduced cost, with simultaneous increase in accuracy, combo-detection of Hepatitis and other viruses, and elimination of refrigerated reagents. It will address the above crisis, the HIV-VL PoC market, and has the potential to disrupt the €1B viral clinical diagnostics market and displace RT-PCR diagnostics that have been used in laboratories for two decades.
Following a successful SME-Phase-1 feasibility, the technology received a Seal-of-Excellence in Phase-2(PHC-12-2015) – exceeded funding threshold. TRL improvements have been made in 2016, and a new CEO, management structure, and new venture funding significantly enhances AltraTech capacity to commercialise EASIVIRAL and see it reach market acceptance. The outcomes will enable capture a market leading share of > 30% of the €210M PoC HIV-VL market, reach cumulative EBITDA for this product alone of more than €18M by 2024. AltraTech will create 75 new jobs during this time, grow its portfolio of granted patents on its disruptive EASIVIRAL technology, and increase the revenues, jobs, and competitiveness of its manufacturing supply partners

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2016-2017

Koordinator

ALTRATECH LIMITED
Netto-EU-Beitrag
€ 2 969 000,00
Adresse
4TH FLOOR 103/104 O CONNELL STREET
V94 AT85 Limerick
Irland

Auf der Karte ansehen

KMU

Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).

Ja
Region
Ireland Southern Mid-West
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 2 969 000,00